Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Geraghty

Vascular Surgery Saint Louis, MO Medical Doctor

NPI 1376560821 CMS profile 17306

4921 Parkview Pl, Div Surg Vascular, Ste 8B, Saint Louis, MO 63110

Open in the dashboard

General payments

$65,375

219 records reported · program years 2019–2025

Research payments

$51,554

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$82,055 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Patrick Geraghty of Saint Louis, MO is reported in the CMS Open Payments database as having received $65,375 across 219 general payments and $51,554 in research payments paid to them. Separately, studies naming them as principal investigator received $82,055 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,624 29
2024 General $1,963 22
2024 Research $51,554 1
2023 General $4,741 41
2022 General $3,041 27
2021 General $36,227 36
2020 General $1,391 13
2019 General $15,388 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Geraghty
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Patrick Geraghty were reported at $2,624. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Patrick Geraghty Vascular Surgery median Middle half National median
2019 $15,388 $796 $226–$2,363 $163
2020 $1,391 $348 $118–$1,110 $114
2021 $36,227 $471 $158–$1,421 $132
2022 $3,041 $725 $222–$2,183 $149
2023 $4,741 $836 $257–$2,440 $160
2024 $1,963 $909 $252–$2,619 $164
2025 $2,624 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bard Peripheral Vascular, Inc. $42,301 34 payments
  2. Boston Scientific Corporation $6,858 18 payments
  3. Medtronic, Inc. $3,169 30 payments
  4. W. L. Gore & Associates, Inc. $2,272 35 payments
  5. LimFlow Inc. $1,610 8 payments
  6. Elite Orthopedics, LLC $1,200 1 payment
  7. InspireMD Ltd $1,073 10 payments
  8. Penumbra, Inc. $969 7 payments
  9. Surmodics, Inc. $917 14 payments
  10. Philips Electronics North America Corporation $857 11 payments
  11. Other $4,148 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $38,344 7 payments
  2. Food and Beverage $14,955 180 payments
  3. Travel and Lodging $10,876 31 payments
  4. Education $1,200 1 payment
Products named General payments · program years 2019–2025
  1. LUTONIX BD Interventional Peripheral Intervention $14,400 1 payment
  2. LIFESTREAM $5,495 3 payments
  3. GENERAL VASCULAR INTERVENTION $5,225 9 payments
  4. TurboHawk $1,936 16 payments
  5. LIMFLOW SYSTEM $1,610 8 payments
  6. Tack Endovascular System $770 2 payments
  7. LUTONIX Peripheral Vascular $766 7 payments
  8. FLOWTRIEVER CATHETER, S $715 5 payments
  9. GORE VIABAHN VBX Balloon Expandable Endo $681 5 payments
  10. CGuard Prime Carotid Stent System $660 9 payments
  11. Other $14,706 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. InspireMD Ltd $51,554 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

179

Median for Vascular Surgery: 122

Drug cost

$30,465

Median for Vascular Surgery: $14,135

Branded share of claims

89.4%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 38 $29,469
Clopidogrel Clopidogrel Bisulfate Brand 122 $970
Prednisone Generic 19 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 108 billing codes

Paid by Medicare

$194,813

Medicare's payments for the services billed

Medicare patients

1,646

Average age 71

Services billed

2,583

740 women, 906 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 50%
Chronic kidney disease 50%
Diabetes 46%
Heart failure 42%
Atrial fibrillation 34%
Depression 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record